RJMty19, developed by Guangdong Ruishun Biotech Co., Ltd, represents a novel approach in the treatment of refractory systemic lupus erythematosus (SLE) through the use of allogeneic CAR-T cell therapy. The market for SLE therapies is growing, driven by the increasing prevalence of the disease and the limitations of current treatment options. The competitive landscape includes established biologics like belimumab and rituximab, but RJMty19's unique mechanism may offer advantages in efficacy and safety. The trial's focus on safety, maximum tolerated dose, and preliminary efficacy positions it well for potential market entry, contingent upon successful outcomes. Diligence should focus on regulatory pathways, potential partnerships for commercialization, and the evolving landscape of CAR-T therapies in autoimmune diseases.